BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33377184)

  • 1. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.
    De Rosa S; Cutuli SL; Ferrer R; Antonelli M; Ronco C;
    Artif Organs; 2021 Jun; 45(6):E187-E194. PubMed ID: 33377184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
    Klein DJ; Foster D; Walker PM; Bagshaw SM; Mekonnen H; Antonelli M
    Intensive Care Med; 2018 Dec; 44(12):2205-2212. PubMed ID: 30470853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry.
    Forin E; Lorenzoni G; Ferrer R; De Cal M; Zanella M; Marchionna N; Gregori D; Forfori F; Lorenzin A; Danzi V; Ronco C; De Rosa S
    Sci Rep; 2023 Oct; 13(1):17600. PubMed ID: 37845296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients.
    Lee CT; Tu YK; Yeh YC; Chang T; Shih PY; Chao A; Huang HH; Cheng YJ; Yeh YC;
    J Crit Care; 2018 Feb; 43():202-206. PubMed ID: 28915395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
    Payen DM; Guilhot J; Launey Y; Lukaszewicz AC; Kaaki M; Veber B; Pottecher J; Joannes-Boyau O; Martin-Lefevre L; Jabaudon M; Mimoz O; Coudroy R; Ferrandière M; Kipnis E; Vela C; Chevallier S; Mallat J; Robert R;
    Intensive Care Med; 2015 Jun; 41(6):975-84. PubMed ID: 25862039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.
    Srisawat N; Tungsanga S; Lumlertgul N; Komaenthammasophon C; Peerapornratana S; Thamrongsat N; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Tungsanga K; Kellum JA
    Crit Care; 2018 Oct; 22(1):279. PubMed ID: 30367647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
    Klein DJ; Foster D; Schorr CA; Kazempour K; Walker PM; Dellinger RP
    Trials; 2014 Jun; 15():218. PubMed ID: 24916483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model.
    Nakata H; Yamakawa K; Kabata D; Umemura Y; Ogura H; Gando S; Shintani A; Shiraishi A; Saitoh D; Fujishima S; Mayumi T; Kushimoto S; Abe T; Shiino Y; Nakada TA; Tarui T; Hifumi T; Otomo Y; Okamoto K; Kotani J; Sakamoto Y; Sasaki J; Shiraishi SI; Takuma K; Tsuruta R; Hagiwara A; Masuno T; Takeyama N; Yamashita N; Ikeda H; Ueyama M; Fujimi S;
    Shock; 2020 Nov; 54(5):667-674. PubMed ID: 32195922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study.
    Nakamura Y; Kitamura T; Kiyomi F; Hayakawa M; Hoshino K; Kawano Y; Yamasaki R; Nishida T; Mizunuma M; Ishikura H;
    Crit Care; 2017 Jun; 21(1):134. PubMed ID: 28592318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study.
    Lee WY; Kim HJ; Kim EY
    Sci Rep; 2021 Dec; 11(1):24132. PubMed ID: 34916567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue therapy with polymyxin B hemoperfusion in high-dose vasopressor therapy refractory septic shock.
    Monti G; Terzi V; Calini A; Di Marco F; Cruz D; Pulici M; Brioschi P; Vesconi S; Fumagalli R; Casella G
    Minerva Anestesiol; 2015 May; 81(5):516-25. PubMed ID: 25319136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis.
    Fujii T; Ganeko R; Kataoka Y; Featherstone R; Bagshaw SM; Furukawa TA
    BMJ Open; 2016 Nov; 6(11):e012908. PubMed ID: 27872122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
    Fujii T; Ganeko R; Kataoka Y; Furukawa TA; Featherstone R; Doi K; Vincent JL; Pasero D; Robert R; Ronco C; Bagshaw SM
    Intensive Care Med; 2018 Feb; 44(2):167-178. PubMed ID: 29204670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry.
    Cutuli SL; Artigas A; Fumagalli R; Monti G; Ranieri VM; Ronco C; Antonelli M;
    Ann Intensive Care; 2016 Dec; 6(1):77. PubMed ID: 27502196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct hemoperfusion with a polymyxin B column versus vasopressin for gram negative septic shock: a matched cohort study of the effect on survival.
    Sawa N; Ubara Y; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Suwabe T; Uchida N; Wake A; Taniguchi S; Takaichi K
    Clin Nephrol; 2013 Jun; 79(6):463-70. PubMed ID: 23253903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertain Clinical Effect of Polymyxin B Hemoperfusion in Patients with Septic Acute Kidney Injury Requiring Continuous Renal Replacement Therapy.
    Lee JM; Baek SD; Kim TH; Jeon HR; Han JH; Chang JW
    Shock; 2021 Oct; 56(4):551-556. PubMed ID: 33606479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of endotoxin adsorption therapy (polymyxin B hemoperfusion) for methicillin-resistant Staphylococcus aureus toxic shock syndrome: a case report about five patients.
    Taniguchi T; Sato K; Kurita A; Noda T; Okajima M
    Minerva Anestesiol; 2013 Jul; 79(7):758-61. PubMed ID: 23635997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endotoxin activity trend and multi-organ dysfunction in critically ill patients with septic shock, who received Polymyxin-B hemadsorption: A multicenter, prospective, observational study.
    Cutuli SL; De Rosa S; Ferrer R; Ruiz-Rodriguez JC; Forfori F; Ronco C; Antonelli M;
    Artif Organs; 2023 Aug; 47(8):1361-1370. PubMed ID: 37767775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection.
    Saito N; Sugiyama K; Ohnuma T; Kanemura T; Nasu M; Yoshidomi Y; Tsujimoto Y; Adachi H; Koami H; Tochiki A; Hori K; Wagatsuma Y; Matsumoto H
    PLoS One; 2017; 12(3):e0173633. PubMed ID: 28358803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VASOPRESSOR REDUCTION EFFECT OF POLYMYXIN B HEMOPERFUSION IN PATIENTS WITH PERITONITIS-INDUCED SEPTIC SHOCK: A PROPENSITY SCORE-MATCHED ANALYSIS.
    Cho A; Oh SY; Lee H; Ryu HG
    Shock; 2024 Jul; 62(1):69-73. PubMed ID: 38661146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.